Sugi Predict

Sugi Predict / Compounds / SCHEMBL1358010

SCHEMBL1358010

SCHEMBL1358010

C[C@H](c1c(O)ccc(F)c1Cl)c1c[nH]c2ncc(Br)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 2/20 0.40
▸ MEN1 O00255 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ PPARG P37231 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ NCOA2 Q15596 1/20 0.38
▸ NCOA1 Q15788 1/20 0.38
▸ NCOA3 Q9Y6Q9 1/20 0.38
▸ ITK Q08881 5/20 0.38
▸ DYRK1A Q13627 4/20 0.38
▸ CLK2 P49760 2/20 0.38
▸ CLK4 Q9HAZ1 2/20 0.38
▸ JAK2 O60674 2/20 0.38
▸ PLK4 O00444 1/20 0.38
▸ AURKA O14965 1/20 0.38
▸ ROCK2 O75116 1/20 0.38
▸ PRKD3 O94806 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27910785 1.00 MET (0.40) METMEN1TP53MAPTHPGD
Tert-Butyl Formate SCHEMBL27910775 0.90 MET (0.36) METMEN1TP53MAPTHPGD
SCHEMBL1358491 0.89 MET (0.48) METITKDYRK1ACLK2CLK4
SCHEMBL1359421 0.89 MET (0.48) METITKDYRK1ACLK2CLK4
SCHEMBL1357809 0.89 MET (0.48) METITKDYRK1ACLK2CLK4
SCHEMBL1359186 0.85 MET (0.43) METITKDYRK1ACLK2CLK4
SCHEMBL1357897 0.85 MET (0.43) METITKDYRK1ACLK2CLK4
SCHEMBL1359293 0.85 MET (0.43) METITKDYRK1ACLK2CLK4
SCHEMBL1359403 0.84 MET (0.42) METITKDYRK1ACLK2CLK4
SCHEMBL1357571 0.84 MET (0.42) METITKDYRK1ACLK2CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2569314-B1 FUSED BICYCLIC KINASE INHIBITORS OSI PHARMACEUTICALS LLC (US) 2016-09-07 — — EP disclosed
US-20130253197-A1 FUSED BICYCLIC KINASE INHIBITORS OSI Pharmaceuticals, LLC (US) 2013-09-26 — — US disclosed
US-8445510-B2 Fused bicyclic kinase inhibitors OSI Pharmaceuticals, LLC (US) 2013-05-21 — — US disclosed
EP-2569314-A1 FUSED BICYCLIC KINASE INHIBITORS OSI Pharmaceuticals, LLC (US) 2013-03-20 — — EP disclosed
CN-102971316-A Fused bicyclic kinase inhibitors OSI PHARMACEUTICALS LLC 2013-03-13 — — CN disclosed
WO-2011143645-A1 FUSED BICYCLIC KINASE INHIBITORS OSI Pharmaceuticals, LLC (US) 2011-11-17 — — WO disclosed
US-20110281888-A1 Fused Bicyclic Kinase Inhibitors OSI Pharmaceuticals, LLC 2011-11-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281888-A1 Fused Bicyclic Kinase Inhibitors ALK, RET, MET MET 3/4885MEN1 519/4885TP53 160/4885
US-20130253197-A1 FUSED BICYCLIC KINASE INHIBITORS ALK, RET, MET MET 3/4885MEN1 519/4885TP53 160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.